Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7

International Congress Series

Volumn 1219, Issue C, 2001, Pages 999-1005

  Wyde, Philip R ^a   Guzman, Efrain ^a   Gilbert, Brian E ^a   Couch, Robert B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvants; Antibodies; Influenza vaccines; MPL; QS 21

Indexed keywords

EID: 85023099410     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00411-3     Document Type: Article

References (15)

1. Remarque, E.J., Influenza vaccination in elderly people. Exp. Gerontol. 34 (1999), 445–452.
2. Palache, A.M., Beyer, W.E., Sprenger, M.J., Masurel, N., de Jonge, S., Vardy, A., et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose–response study in elderly nursing-home residents and young volunteers. Vaccine 11 (1993), 3–9.
3. Powers, D.C., Belshe, R.B., Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J. Infect. Dis. 167 (1993), 584–592.
4. Couch, R.B., Keitel, W.A., Cate, T.R., Quarles, J.A., Taber, L.A., Glezen, W.P., Prevention of influenza virus infections by current inactivated influenza virus vaccines. Brown, L.E., Hampson, A.W., Webster, R.G., (eds.) Options for the Control of Influenza III, 1996, Elsevier, Amsterdam, 97–106.
5. Gupta, R.K., Siber, G.R., Adjuvants for human vaccines—current status, problems and future prospects. Vaccine 13 (1995), 1263–1276.
6. O'Hagan, D.T., Recent advances in vaccine adjuvants for systemic and mucosal administration. J. Pharm. Pharmacol. 49 (1997), 1–10.
7. Baldridge, J.R., Crane, R.T., Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19 (1999), 103–107.
8. Kensil, C.R., Wu, J.Y., Anderson, C.A., Wheeler, D.A., Amsden, J., QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92 (1998), 41–47.
9. Allison, A.C., Byars, N.E., Immunological adjuvants and their mode of action. Ellis, R.W., (eds.) Vaccines: New Approaches to Immunologic Problems, 1992, Butterworth-Heinemann, Stoneham, MA, 431–449.
10. Hennessy, A.V., Davenport, F.M., Relative merits of aqueous and adjuvant influenza vaccines when used in a two-dose schedule. Public Health Rep. 76 (1961), 411–419.
11. Salk, J.E., Bailey, M.L., Laurent, A.M., The use of adjuvants in studies on influenza immunization: II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water-in-oil emulsion. Am. J. Hyg. 55 (1952), 439–456.
12. Wyde, P.R., Gilbert, B.E., Levy, B.M., Evidence that T-lymphocytes are part of the blood–brain barrier to virus dissemination. J. Neuroimmunol. 5 (1983), 47–58.
13. Robinson, R.Q., Dowdle, W.R., Influenza viruses. Schmidt, E.H., Lennette, N.J., (eds.) Diagnostic Procedures for Viral and Rickettsial Infections, 1969, American Public Health Association, New York, NY, 414–433.
14. Tamura, S.-I., Samegai, Y., Kurate, H., Nagamine, T., Aizawa, C., Kurata, T., Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6 (1988), 409–413.
15. Sokal, R.R., Rohlf, F.J., Biometry, 1969, Freeman, San Francisco, 370.